

This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).


A TRANSGENIC MOUSE LINE EXPRESSING AN
AMYLOIDOGENIC HUMAN TRANSTHYRETIN


STEVEN R. ZELDENRUST

Submitted to the faculty of the University Graduate School
in partial fulfillment of the requirements
for the degree
Doctor of Philosophy
in the Department of Medical and Molecular Genetics
Indiana University


July 2001


Accepted by the Graduate Faculty, Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy.

Co-Chairman: 
Merrill D. Benson, M.D.
Professor, Departments of Medicine
and Pathology and Laboratory
Medicine

Co-Chairman: 
David A. Williams, M.D.
Professor, Department of Pediatrics
Associate Professor, Department of
Medical and Molecular Genetics

Doctoral Committee


Stephen R. Dlouhy, Ph.D.
Associate Scientist
Departments of Medical and
Molecular Genetics and Pathology
And Laboratory Medicine


Yan Chen, M.D., Ph.D.
Assistant Professor, Department of
Medical and Molecular Genetics

January 26, 2001

Steven R. Zeldenrust

A TRANSGENIC MOUSE LINE EXPRESSING AN
AMYLOIDOGENIC HUMAN TRANSTHYRETIN

ABSTRACT

Amyloidosis is a group of conditions characterized by the deposition of insoluble protein fibrils. Deposits can occur either locally or systemically, depending on the protein involved. Systemic amyloidosis may occur sporadically (Immunoglobulin, AL), secondary to inflammatory disease (Reactive, AA) or in an inherited fashion (Hereditary, AH). Hereditary amyloidosis, also known as Familial Amyloidotic Polyneuropathy (FAP), is transmitted as an autosomal dominant trait. In most of the hereditary forms the amyloid protein has been identified as transthyretin (TTR), a plasma protein. Most of the known cases of transthyretin amyloidosis result from variant proteins containing a single amino acid substitution. Other proteins, such as apolipoprotein AI, gelsolin, fibrinogen, cystatin C and lysozyme have been shown to cause systemic amyloid deposits in some kindreds as well. While much has been discovered about the molecular and biochemical basis of hereditary amyloidosis in recent years, the basic mechanism of amyloid formation remains a mystery. As a result, the current treatment of this condition involves minimizing the damage caused by the amyloid, with liver transplantation the only means of preventing the accumulation of further deposits for those proteins synthesized by the liver. Since hereditary amyloidosis is strictly a disease of humans, research on pathogenesis has been hampered by the lack of a suitable animal model. The main objective of this research is the development of a transgenic mouse line expressing an

amyloidogenic human transthyretin gene.

The initial step involved isolating a full-length variant TTR gene from an affected individual. The intact mutant gene, along with upstream sequence, was cloned and used to create several lines of transgenic mice by the pronucleus microinjection technique. Several of these lines demonstrated high expression levels of variant human TTR in their serum and subsequent breedings confirmed transmission of the transgene. The pattern of expression of the transgene in various tissues in the mouse was found to parallel the known pattern of expression in humans. This suggests that regulatory sequences in the upstream region of the transgene are appropriately controlling expression in the mouse.

Histopathological examination of representative members of each line was conducted at regular intervals for evidence of amyloid formation. Two animals have developed amyloid deposits composed of serum amyloid A protein, but no transthyretin amyloid was seen. Even without evidence of transthyretin amyloid formation, this animal model serves a useful role in basic research in finding a cure for this debilitating condition.

Table of Contents

<u>Literature Review</u>	<u>Page</u>
Introduction	1
Amyloidosis	2
Hereditary Systemic Amyloidosis	6
Apolipoprotein AI	7
Cystatin C	13
Fibrinogen	13
Gelsolin	16
Lysozyme	17
Transthyretin	19
Transthyretin Amyloidosis	25
Ocular Manifestations of Amyloidosis	27
Animal Models of FAP	29
Treatment of Amyloidosis	35
<u>Material and Methods</u>	
Isolation of DNA	42
Construction of Genomic Library	42
Isolation of Full-Length I84S TTR Clone	45
Partial Restriction Mapping of I84S TTR Clone	48
Direct Sequencing of TTR Genomic Clone	50
Transfection of H7 Cells with I84S Human TTR Insert	50
Analysis of Transfected H7 Cells	52
Template Construction for Reverse Transcription PCR	53
Reverse Transcription PCR of H7 Clones	55
Construction of Transgenic Mice	55
Analysis of Transgenic Mice	57
ELISA Analysis of Transgenic Mouse Serum	58
Western Blot Analysis of Transgenic Mouse Serum	59
Transgenic Tissue Expression Pattern Determination	59
Congo Red Staining for Amyloid Deposits	60
Primary Hepatocyte Isolation	61

<u>Results</u>	<u>Page</u>
Isolation of Full-Length I84S TTR Genomic Clone	63
Transfection of Mouse H7 Cells	77
Construction and Characterization of Transgenic Mice	80
Primary Hepatocyte Culture	93
<u>Discussion</u>	
Isolation of Full-Length I84S TTR Gene	95
Transfection of H7 Cells	100
Construction and Characterization of Transgenic Mice	103
Attempts to Affect Regulation of the Transgene	113
<u>Conclusion</u>	117
<u>References</u>	126
<u>Curriculum Vitae</u>	164